Biochips (Microarrays/Microfluidics) Global Market – Forecast To 2023

Report ID : RNR-90936 Category : Biotechnology Published Date : June 2017
Publisher : 9Dimen Pages : 404 Format : PDF
Biochips (Microarrays/Microfluidics) Global Market – Forecast To 2023 

Biochips come handy as thousands of experiments are performed on a small chip with a solid platform and acts like a mini laboratory. Usage of biochips has increased in the past decade as its application varies from high throughput screening in drug discovery to personalized medicine. 

The global biochips market is expected to grow at double digit CAGR to reach $17,851.1 million by 2023. Biochips market is mainly classified into technologies, products, application and end-users. The global biochips market is broadly classified as micro arrays and microfluidics based on technology. Based on products, the market is classified into Instruments, Reagents & Consumables and Software & Services. Biochips market is segmented on the basis of application as Genomics, Proteomics, Drug discovery, Diagnostics, Food & agricultural testing and others. Genomics application segment is further classified into SNP Genotyping, Gene Expression and Others where as Drug discovery segment is further sub segmented into Target Identification & Validation, HTS (High Throughput screening) and Lead Optimization. Diagnostics segment is further divided into Cancer diagnostics and other diagnostics. End-Users are further classified into Pharmaceutical & Biotech companies, Academic & Research laboratories, Diagnostic laboratories, CROs (Contract and Research Organizations) and others. 

Among microarrays and Microfluidics, Microfluidics occupies the major share in 2016 and is expected to grow at a highest CAGR from 2016 to 2023. Among products Reagents & consumables occupy the major share of XX% in 2016 and are expected to grow at a CAGR of XX% from 2016 to 2023 to reach $XX million by 2023. Among Application segment Diagnostics commanded the larger revenue in 2016 and is expected to grow at a highest CAGR of XX% from 2016 to 2023. Among Genomics, SNP genotyping occupies a major share in 2016 with a CAGR of XX% from 2016 to 2023. Target Identification & Validation in Drug discovery segment occupies a major share of XX% in 2016 and similarly other diagnostics occupies a major share of XX% in 2016 and grows with a CAGR of XX% from 2016 to 2023. Diagnostic laboratories occupy a major share of XX% in 2016 and grow with a maximum CAGR of XX% from 2016 to 2023. 

Revolution in the field of genomics, proteomics as well as rapid drug discovery increased the demand for biochips. In addition, increase in diagnosis and treatment of cancer and genetic diseases, approval for personalized medicines and invention of novel technologies in biochips drives the market of biochips. Standardization and quality assurance of biochips, technological ease in handling the biochips especially in the areas of diagnosis and treatment, high cost along with ethical and social issues hinders the market growth. 

Lifestyle changes owing to increase in cancer, diabetes and hypertension patients, early diagnosis and treatment of diseases, advancement of biochips with its wide application areas shows that biochip market has vast opportunities in the coming years. 

North America accounts for the highest market share in 2016 and followed by Europe. Steep rise in genetic diagnosis, huge corporate outsourcing for drug discovery, increase in personalized medicines and favourable government policies makes U.S. the leader of Biochips market. However, Asian countries especially China and Japan are the fastest growing regions with its growing demand for biochips and increasing research investments. Asia-Pacific grows with a highest CAGR of XX% from 2016 to 2023. 

Major players in biochips market include Abbott laboratories (U.S.), Agilent Technologies (U.S.), Becton-Dickinson Company (U.S.), Bio-Rad Laboratories (U.S.), Danaher Corporation (U.S.), Fluidigm Corporation (U.S.), GE Healthcare (U.S.), Illumina (U.S.), PerkinElmer, Inc. (U.S.) and Thermo Fisher Scientific, Inc. (U.S.). 

The report provides an in depth market analysis of the above mentioned segments across the following regions:
North America
Rest of the World
1 Executive Summary
2 Introduction
2.1 Key Take Aways
2.2 Report Description
2.3 Markets Covered
2.4 Stakeholders
2.5 Research Methodology
2.5.1 Market Size Estimation
2.5.2 Market Breakdown And Data Triangulation
2.5.3 Secondary Sources
2.5.4 Primary Sources
2.5.5 Key Data Points From Secondary Sources
2.5.6 Key Data Points From Primary Sources
2.5.7 Assumptions
3 Market Analysis
3.1 Introduction
3.2 Market Segmentation
3.3 Factors Influencing Market
3.3.1 Drivers And Opportunities Increase In Usage Of Biochips In Cancer Diagnostics Biochips Preference In Personalized Medicine Widening Application Market Emerging Asia Pacific Market Increased Government Funding
3.3.2 Restraints And Threats High Cost Of Biochips Lack Of Standardization Limited Skilled Personnel To Work On Biochips Stringent Regulations Adoption Of Ngs
3.4 Porter’s Five Force Analysis
3.4.1 Threat Of New Entrants
3.4.2 Threat Of Substitutes
3.4.3 Rivalry Among Existing Competitors
3.4.4 Bargaining Power Of Suppliers
3.4.5 Bargaining Power Of Buyers
3.5 Regulatory Guidelines
3.5.1 United States
3.5.2 Europe
3.5.3 China
3.5.4 India
3.5.5 Japan
3.6 Market Share Analysis By Major Players
3.6.1 Microarray Technology Global Market Share Analysis By
Major Players
3.6.2 Microfluidic Technology Global Market Share Analysis
By Major Players
3.7 Patent Trends
3.8 Supply Chain Analysis
3.9 Biochips Under Clinical Trial
3.10 New Product Launches
3.11 Technological Advancements
3.11.1 “Lab On A Chip’ That Costs 1 Cent To Make
3.11.2 Light Based Lab-On-A-Chip Device
3.11.3 New Neuro Chip
3.11.4 3d Printed Organ-On-A-Chip
3.11.5 Liquid Biopsy Chips For The Detection Of Metastatic
Cancer Cells
3.11.6 Placenta On A Chip
4 Biochips Global Market, By Technology
4.1 Introduction
4.2 Microarrays
4.2.1 Dna Microarrays
4.2.2 Protein Microarrays
4.2.3 Tissue Microarrays
4.2.4 Cell Microarrays
4.2.5 Other Microarrays
4.3 Lab-On-A-Chip (Microfluidics)
4.3.1 Pcr-On-A-Chip
4.3.2 Immunoassays-On-A-Chip
4.3.3 Electrophoresis-On-A-Chip
4.3.4 Flow Cytometry-On-A-Chip
4.3.5 Ngs-On-A-Chip
4.3.6 Organ-On-Chip
4.3.7 Others
5 Biochips Global Market, By Products
5.1 Introduction
5.2 Instruments
5.3 Reagents And Consumables
5.4 Software And Services
6 Biochips Global Market, By Applications
6.1 Introduction
6.2 Genomics
6.2.1 Gene Expression
6.2.2 Snp Genotyping
6.2.3 Other Genomics
6.3 Proteomics
6.4 Drug Discovery & Development
6.4.1 Target Identification And Validation
6.4.2 High Throughput Screening
6.4.3 Lead Optimization
6.5 Diagnostics
6.5.1 Cancer Diagnostics
6.5.2 Other Diagnostics
6.6 Food And Agriculture Testing
6.7 Others
7 Biochips Global Market, By End-Users
7.1 Introduction
7.2 Pharmaceutical And Biotech Companies
7.3 Academic & Research Laboratories
7.4 Contract Research Organisations
7.5 Diagnostic Laboratories
7.6 Others
8 Regional Market Analysis
8.1 Introduction
8.2 North America
8.2.1 U.S.
8.2.2 Others
8.3 Europe
8.3.1 Germany
8.3.2 U.K.
8.3.3 France
8.3.4 Others
8.4 Asia-Pacific
8.4.1 China
8.4.2 Japan
8.4.3 India
8.4.4 Others
8.5 Rest Of The World
8.5.1 Brazil
8.5.2 Rest Of Latin America
8.5.3 Middle East And Others
9 Competitive Landscape
9.1 Introduction
9.2 New Product Launches
9.3 Agreements, Partnership, Collaboration & Joint Ventures
9.4 Approvals
9.5 Mergers & Acquisitions
9.6 Other Developments
10 Major Companies
10.1 Abbott Laboratories
10.1.1 Overview
10.1.2 Financials
10.1.3 Product Portfolio
10.1.4 Key Developments
10.1.5 Business Strategy
10.1.6 Swot Analysis
10.2 Agilent Technologies, Inc.
10.2.1 Overview
10.2.2 Financials
10.2.3 Product Portfolio
10.2.4 Key Developments
10.2.5 Business Strategy
10.2.6 Swot Analysis
10.3 Becton Dickinson And Company
10.3.1 Overview
10.3.2 Financials
10.3.3 Product Portfolio
10.3.4 Key Developments
10.3.5 Business Strategy
10.3.6 Swot Analysis
10.4 Bio-Rad Laboratories
10.4.1 Overview
10.4.2 Financials
10.4.3 Product Portfolio
10.4.4 Key Developments
10.4.5 Business Strategy
10.4.6 Swot Analysis
10.5 Danaher Corporation
10.5.1 Overview
10.5.2 Financials
10.5.3 Product Portfolio
10.5.4 Key Developments
10.5.5 Business Strategy
10.5.6 Swot Analysis
10.6 Fluidigm Corporation
10.6.1 Overview
10.6.2 Financials
10.6.3 Product Portfolio
10.6.4 Key Developments
10.6.5 Business Strategy
10.6.6 Swot Analysis
10.7 Ge Healthcare
10.7.1 Overview
10.7.2 Financials
10.7.3 Product Portfolio
10.7.4 Key Developments
10.7.5 Business Strategy
10.7.6 Swot Analysis
10.8 Illumina, Inc.
10.8.1 Overview
10.8.2 Financials
10.8.3 Product Portfolio
10.8.4 Key Developments
10.8.5 Business Strategy
10.8.6 Swot Analysis
10.9 Perkinelmer, Inc.
10.9.1 Overview
10.9.2 Financials
10.9.3 Product Portfolio
10.9.4 Key Developments
10.9.5 Business Strategy
10.9.6 Swot Analysis
10.10 Thermofisher Scientific Inc.
10.10.1 Overview
10.10.2 Financials
10.10.3 Product Portfolio
10.10.4 Key Developments
10.10.5 Business Strategy
10.10.6 Swot Analysis